Quantcast

Latest Imatinib Stories

2008-10-29 15:00:27

Oregon Health & Science University today announced that Philip H. and Penny Knight have pledged to give $100 million to the OHSU Cancer Institute. The Nike founder's gift - the largest in the history of OHSU - represents a critical step toward achieving the cancer institute's ambitious goal to make Oregon's cancer death rate the lowest in the nation. In recognition of the transformational impact the donors' generosity will have on the treatment of cancer, OHSU will rename its cancer...

2008-10-27 06:00:23

GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today reported that pre-clinical data on RGB-286638, the Company's multi-targeted protein kinase inhibitor, were presented at the 20th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics in Geneva, Switzerland in a poster entitled, "RGB-286638 is a novel multi-targeted protein kinase inhibitor with activity in chronic myelogenous leukemia (CML) models," (Abstract #578). The data presented demonstrate that the...

2008-10-16 09:00:42

Exelixis, Inc. (Nasdaq:EXEL) announced today that it will present 15 posters on the company's investigational compounds at the 20th Annual European Organization for Research and Treatment of Cancer-National Cancer Institute-American Academy of Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer Therapeutics," which will be held October 21-October 24 in Geneva, Switzerland. The titles, schedules, and locations for the poster presentations are provided below. Note that...

2008-10-08 09:00:12

EAST HANOVER, N.J., Oct. 8 /PRNewswire-FirstCall/ -- An early proof-of-concept study presented today shows promising results for imatinib mesylate in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder. Preliminary findings from a 59-patient, multi-center Phase II clinical trial suggest imatinib mesylate provides a treatment benefit, as demonstrated by a significant improvement in pulmonary vascular resistance and a numerical increase in...

2008-09-11 09:00:48

According to a new study by Cutting Edge Information, tyrosine kinase inhibitors may have five oncology drugs with annual sales over $1 billion by 2013. This list of blockbuster oncology drugs includes Novartis' Gleevec. Annual sales of Gleevec are projected to steadily grow to $4.6 billion dollars in 2012, making it a top five oncology drug. There are four other approved tyrosine kinase inhibitors that are estimated to surpass $1 billion in annual sales by 2013, one of which is Pfizer's...

2008-08-27 09:00:23

EAST HANOVER, N.J., Aug. 27 /PRNewswire/ -- Novartis announced today that Gleevec(R) (imatinib mesylate) tablets* has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST). FDA priority review status is granted to therapies that could potentially fill a currently unmet medical need and accelerates the standard review timing from ten to six months(1)....

2008-07-22 09:01:13

WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that improves exercise capacity by a greater percentage than Actelion's Tracleer at 16 weeks, would earn a 48 percent patient share in the treatment of pulmonary arterial hypertension, according to surveyed pulmonologists. Although other efficacy measures are also important to prescribers, they indicate that...

2008-07-02 09:00:13

Rationale: Platelet-derived growth factor (PDGF) promotes the proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), and may play a role in the progression of pulmonary arterial hypertension (PAH), a condition characterized by proliferation of PASMCs resulting in the obstruction of small pulmonary arteries. Objectives: To analyze the expression and pathogenic role of PDGF in idiopathic PAH. Methods: PDGF and PDGF receptor mRNA expression was studied by real-time...

2008-07-01 09:01:11

ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today that it has submitted the non-clinical section of the rolling submission of a New Drug Application (NDA) for omacetaxine mepesuccinate (formerly known as Ceflatonin(R)) to the U.S. Food and Drug Administration (FDA). "The non-clinical section of the NDA is the first of three parts necessary to complete the NDA submission of omacetaxine and brings us one step closer to commercialization," said Dr. Greg Collier, ChemGenex's...

2008-06-24 02:30:28

U.S. and Swedish researchers say a leukemia drug may help patients benefit from tissue plasminogen activator, or tPA stroke treatment. For more than a decade, the drug tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke but its promise is blemished because: tPA can cause dangerous bleeding in the brain and its brain-saving power fades fast after the third hour of a stroke. Researchers at the University of Michigan and the Ludwig Institute...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related